Oxford BioMedica (LON:OXB) insider Peter Nolan purchased 371,450 shares of the business’s stock in a transaction on Thursday, April 5th. The shares were purchased at an average price of GBX 11 ($0.15) per share, with a total value of £40,859.50 ($57,354.72).
LON OXB opened at GBX 10.96 ($0.15) on Friday. Oxford BioMedica has a 1-year low of GBX 4.44 ($0.06) and a 1-year high of GBX 13.19 ($0.19).
Separately, Peel Hunt restated a “buy” rating on shares of Oxford BioMedica in a report on Wednesday.
ILLEGAL ACTIVITY NOTICE: “Oxford BioMedica (OXB) Insider Buys £40,859.50 in Stock” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/oxford-biomedica-oxb-insider-buys-40859-50-in-stock.html.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.